This is in keeping with the recommendations made by the joint European Society of Breast Cancer Specialists and the International Society of Geriatric Oncology (SIOG) taskforce which recommends CDK4/6 inhibitors as a suitable treatment in older patients given that efficacy is age independent as shown from the pooled analyses of the landmark trials, though higher rates of toxicity and dose modifications were acknowledged in those aged ≥75 years [23]. This evidence concerns the gene CDK4 and breast carcinoma.